CollPlant Biotechnologies Ltd. Sponsored ADR

CLGN Healthcare Biotechnology

CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.

3.63 0.05 −1.36%
Market cap
$7.0M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
4/9
Altman Z
−16.87
Beneish M
−3.20
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
2 2 4 4

+8 more TTM periods

ROE
(161.98%) (151.99%) (117.56%) (92.74%)
ROA
(101.59%) (99.53%) (77.90%) (66.57%)
ROIC
0.00% (3,125.00%) (5,478.53%) (1,612.55%)
Return on Tangible Assets
(509.49%) (300.55%) (207.46%) (140.76%)
Average Days of Receivables
464.86 218.62 34.48 37.46
Free Cash Flow per Share
(7.76) (8.24) (7.74) (7.87)
Free Cash Flow
(11.20) (11.33) (9.45) (10.02)
Capital Expenditures
(0.01) (0.02) (0.03) (0.07)
Other line items
Cash ROIC
(189.99%) (119.06%) (78.51%) (55.25%)
Accounts Receivable Turnover
0.83 1.16 5.88 7.23
Accounts Payable Turnover
3.24 1.37 1.13 1.12
Inventory Turnover
2.45 1.42 1.65 1.84
Average Days of Payables
69.68 240.68 266.65 246.52
Days of Inventory on Hand
146.98 257.36 250.47 215.41
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
2,173.58% 1,994.86% 345.30% 353.54%
Selling, General and Administrative Expense of Revenue
1,405.66% 1,186.63% 203.80% 206.75%
Share Based Compensation of Revenue
191.51% 204.88% 42.13% 58.22%
Interest Coverage
(30.26) — — —
Operating CF/Net income
0.89 0.86 0.82 0.82
Depreciation/Fixed assets
0.81 0.69 0.62 0.57
Capex/Depreciation
(0.01) (0.03) (0.03) (0.07)
Revenue per Share
0.22 0.28 1.94 1.95
Operating CF per Share
(7.76) (8.22) (7.72) (7.82)
Capex per Share
(0.01) (0.02) (0.02) (0.05)
Capex to Sales
0.03 0.06 0.01 0.03

Fold the line items

Columns are period end dates · fundamentals updated 6 Oct 2026